FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580131221> ?p ?o ?g. }

• W2580131221 abstract "Abstract Introduction: The management of venous thromboembolism (VTE) and the prevention of recurrent VTE consists of anticoagulation primarily with Vitamin K Antagonists (VKA). The main adverse effect of anticoagulation is bleeding. This study aimed to investigate the predictors of major bleeding in patients with first VTE treated with VKA. Methods: A cohort study was undertaken using the United Kingdom's Clinical Practice Research Datalink with additional data from hospitalizations and causes of death. Patients with incident first VTE between 2008-2013 treated with VKA, i.e. starting VKA treatment within 60 days after first VTE, were included in the cohort. Major bleeding was defined in accordance with the International Society of Thrombosis and Haemostasis recommendations comprising fatal bleeds, bleeds at a critical site, and bleeding events in association with anemia or blood transfusions. Patients were followed until the end of the first VKA treatment episode. Hazard ratios of potential predictors for major bleeding during the first VKA treatment episode were estimated from Cox regression models which included recognized predictors for major bleeding before the diagnosis of VTE, and a list of potential predictors during VKA treatment. Results: Among 10,118 VKA-treated VTE patients the incidence rate of major bleeding was 2.6 (95% confidence interval (CI), 2.2-3.1) per 100 person-years (145 major bleeds during 5,548 person-years of VKA use). Among baseline characteristics, predictors for major bleeding (Table) included increasing age, and history of a major bleeding and of a non-major clinically relevant bleeding. Furthermore the following events after the first VTE (80 of 145 cases) were also associated with an increased risk of major bleeding: non-major clinically relevant bleeding, HR 2.88 (95% CI, 1.85 - 4.46), active cancer 4.13 (2.48-6.89), trauma 14.05 (7.96-24.82), surgery 3.27 (1.29-8.28), and medical illness 3.03 (1.87-4.90). Additional predictors for major bleeding were new onset or history of moderate/severe liver disease, 7.44 (2.93-18.92), or renal disease, 1.73 (1.19-2.52). Conclusions: Assessment for and awareness of these predictors prior to and during VKA treatment is needed to prevent major bleeding events. Caution is warranted in patients with these independent risk factors. Table 1. Association between factors at first VTE and during VKA treatment and major bleeding Incident major bleeding after first VTE n (%) Crude hazard ratio (95%-CI) Adjusted hazard ratio (95%-CI) Total 145 (100) Age1 <60 26 (17.93) 1 1 60-69 31 (21.38) 2.03 (1.21 - 3.42) 1.83 (1.07 - 3.14) 70-79 39 (26.90) 2.56 (1.56 - 4.21) 2.19 (1.27 - 3.76) 80+ 49 (33.79) 4.52 (2.81 - 7.28) 3.28 (1.90 - 5.68) Gender Female 72 (49.66) 0.98 (0.71 - 1.35) 0.89 (0.63 - 1.25) Type of first VTE DVT 82 (56.55) 1 1 PE 63 (43.45) 0.91 (0.65 - 1.27) 0.78 (0.56 - 1.09) History of bleeding prior to first VTE Non-major clinically relevant 56 (38.62) 2.09 (1.48 - 2.95) 1.75 (1.23 - 2.49) Major bleeding 13 (8.97) 4.47 (2.48 - 8.05) 3.17 (1.73 - 5.80) Prevalence of prior events at the day of the first VTE (duration of exposure) Active cancer (90 days) 14 (9.66) 2.07 (1.20 - 3.60) 0.75 (0.37 - 1.50) Non-active cancer 14 (9.66) 1.40 (0.81 - 2.43) 0.75 (0.42 - 1.37) Trauma (90 days) 11 (7.59) 1.01 (0.54 - 1.86) 1.09 (0.58 - 2.04) Inpatient surgery (90 days) 13 (8.97) 1.00 (0.57 - 1.77) 0.90 (0.48 - 1.68) Medical illness (90 days) 11 (7.59) 1.14 (0.62 - 2.11) 0.71 (0.35 - 1.42) Liver disease Mild 4 (2.76) 1.62 (0.60 - 4.38) 1.15 (0.42 - 3.17) Moderate/severe 5 (3.45) 6.80 (2.78 - 16.64) 7.44 (2.93 - 18.92) Renal disease 50 (34.48) 2.60 (1.84 - 3.66) 1.73 (1.19 - 2.52) Bleeding after first VTE Non-major clinically relevant 27 (18.62) 3.91 (2.55 - 5.99) 2.88 (1.85 - 4.46) Events after first VTE (duration of exposure) Active cancer (90 days) 32 (22.07) 4.76 (3.19 - 7.10) 4.13 (2.48 - 6.89) Trauma (14 days) 14 (9.66) 16.63 (9.49 - 29.12) 14.05 (7.96 - 24.82) Inpatient surgery (14 days) 5 (3.45) 5.79 (2.33 - 14.37) 3.27 (1.29 - 8.28) Medical illness (90 days) 24 (16.55) 3.24 (2.06 - 5.10) 3.03 (1.87 - 4.90) Disclosures Cohen: BMS: Consultancy, Honoraria, Research Funding, Speakers Bureau; Portola: Consultancy, Honoraria, Research Funding, Speakers Bureau; Daiichi Sankyo: Consultancy, Honoraria, Research Funding, Speakers Bureau; Jannsen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Bayer: Honoraria, Research Funding, Speakers Bureau; Boeheringer Ingelheim: Consultancy, Honoraria. Hamilton:BMS: Employment, Equity Ownership. Unniachan:BMS: Employment, Equity Ownership. Martinez:Bayer: Research Funding; CSL Behring: Research Funding; Pfizer: Research Funding; BMS: Research Funding; Boehringer Ingelheim: Consultancy; Merz Pharma: Research Funding." @default.
• W2580131221 created "2017-02-03" @default.
• W2580131221 creator A5003814460 @default.
• W2580131221 creator A5011644019 @default.
• W2580131221 creator A5022590959 @default.
• W2580131221 creator A5026110306 @default.
• W2580131221 creator A5033748212 @default.
• W2580131221 creator A5088335104 @default.
• W2580131221 date "2015-12-03" @default.
• W2580131221 modified "2023-09-28" @default.
• W2580131221 title "Predictors of Major Bleeding in Patients with First Venous Thromboembolism Treated with Vitamin K Antagonists in Clinical Practice in the United Kingdom" @default.
• W2580131221 doi "https://doi.org/10.1182/blood.v126.23.2327.2327" @default.
• W2580131221 hasPublicationYear "2015" @default.
• W2580131221 type Work @default.
• W2580131221 sameAs 2580131221 @default.
• W2580131221 citedByCount "0" @default.
• W2580131221 crossrefType "journal-article" @default.
• W2580131221 hasAuthorship W2580131221A5003814460 @default.
• W2580131221 hasAuthorship W2580131221A5011644019 @default.
• W2580131221 hasAuthorship W2580131221A5022590959 @default.
• W2580131221 hasAuthorship W2580131221A5026110306 @default.
• W2580131221 hasAuthorship W2580131221A5033748212 @default.
• W2580131221 hasAuthorship W2580131221A5088335104 @default.
• W2580131221 hasConcept C120665830 @default.
• W2580131221 hasConcept C121332964 @default.
• W2580131221 hasConcept C126322002 @default.
• W2580131221 hasConcept C141071460 @default.
• W2580131221 hasConcept C187212893 @default.
• W2580131221 hasConcept C197934379 @default.
• W2580131221 hasConcept C201903717 @default.
• W2580131221 hasConcept C207103383 @default.
• W2580131221 hasConcept C2776301958 @default.
• W2580131221 hasConcept C2776704044 @default.
• W2580131221 hasConcept C2779161974 @default.
• W2580131221 hasConcept C2780011451 @default.
• W2580131221 hasConcept C2780868729 @default.
• W2580131221 hasConcept C3017811039 @default.
• W2580131221 hasConcept C44249647 @default.
• W2580131221 hasConcept C500558357 @default.
• W2580131221 hasConcept C50382708 @default.
• W2580131221 hasConcept C61511704 @default.
• W2580131221 hasConcept C71924100 @default.
• W2580131221 hasConcept C72563966 @default.
• W2580131221 hasConceptScore W2580131221C120665830 @default.
• W2580131221 hasConceptScore W2580131221C121332964 @default.
• W2580131221 hasConceptScore W2580131221C126322002 @default.
• W2580131221 hasConceptScore W2580131221C141071460 @default.
• W2580131221 hasConceptScore W2580131221C187212893 @default.
• W2580131221 hasConceptScore W2580131221C197934379 @default.
• W2580131221 hasConceptScore W2580131221C201903717 @default.
• W2580131221 hasConceptScore W2580131221C207103383 @default.
• W2580131221 hasConceptScore W2580131221C2776301958 @default.
• W2580131221 hasConceptScore W2580131221C2776704044 @default.
• W2580131221 hasConceptScore W2580131221C2779161974 @default.
• W2580131221 hasConceptScore W2580131221C2780011451 @default.
• W2580131221 hasConceptScore W2580131221C2780868729 @default.
• W2580131221 hasConceptScore W2580131221C3017811039 @default.
• W2580131221 hasConceptScore W2580131221C44249647 @default.
• W2580131221 hasConceptScore W2580131221C500558357 @default.
• W2580131221 hasConceptScore W2580131221C50382708 @default.
• W2580131221 hasConceptScore W2580131221C61511704 @default.
• W2580131221 hasConceptScore W2580131221C71924100 @default.
• W2580131221 hasConceptScore W2580131221C72563966 @default.
• W2580131221 hasLocation W25801312211 @default.
• W2580131221 hasOpenAccess W2580131221 @default.
• W2580131221 hasPrimaryLocation W25801312211 @default.
• W2580131221 hasRelatedWork W1864253793 @default.
• W2580131221 hasRelatedWork W2004719936 @default.
• W2580131221 hasRelatedWork W2035728361 @default.
• W2580131221 hasRelatedWork W2472805092 @default.
• W2580131221 hasRelatedWork W2561784286 @default.
• W2580131221 hasRelatedWork W2563749973 @default.
• W2580131221 hasRelatedWork W2588392889 @default.
• W2580131221 hasRelatedWork W2596445459 @default.
• W2580131221 hasRelatedWork W2610621866 @default.
• W2580131221 hasRelatedWork W2907581136 @default.
• W2580131221 hasRelatedWork W2943406097 @default.
• W2580131221 hasRelatedWork W2979589483 @default.
• W2580131221 hasRelatedWork W2980313918 @default.
• W2580131221 hasRelatedWork W2985373788 @default.
• W2580131221 hasRelatedWork W3009736719 @default.
• W2580131221 hasRelatedWork W3096456327 @default.
• W2580131221 hasRelatedWork W3097965302 @default.
• W2580131221 hasRelatedWork W3134415673 @default.
• W2580131221 hasRelatedWork W3195195808 @default.
• W2580131221 hasRelatedWork W4916723 @default.
• W2580131221 isParatext "false" @default.
• W2580131221 isRetracted "false" @default.
• W2580131221 magId "2580131221" @default.
• W2580131221 workType "article" @default.